Literature DB >> 15618952

Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework.

A H Fanous1, K S Kendler.   

Abstract

Schizophrenia has long been thought to be clinically heterogeneous. A range of studies suggests that this is due to genetic heterogeneity. Some clinical features, such as negative symptoms, are associated with a greater risk of illness in relatives. Affected sibling pairs are correlated for clinical and course features as well as subforms of illness, and twin studies suggest that this is due to genetic factors. This is further supported by findings that subjects from families linked to some chromosomal regions may differ clinically from those from unlinked families. Moreover, some genes may affect clinical features without altering susceptibility (ie are modifier genes). High-risk genotypes may have quantitative, rather than categorical effects, and may influence milder or subclinical phenotypes. Another recent finding is that nonpsychotic relatives may have personality features that resemble those of their affected relatives. These findings taken together suggest that there may be several classes of gene action in schizophrenia: some genes may influence susceptibility only, others may influence clinical features only, and still others may have a mixed effect. Furthermore, subsets of these classes may affect personality and other traits in nonpsychotic relatives. Understanding these classes of gene action may help guide the design of linkage and association studies that have increased power. We describe five classes of genes and their predictions of the outcomes of family, twin, and several types of linkage studies. We go on to explore how these predictions can in turn be used to aid in the design of linkage studies.

Entities:  

Mesh:

Year:  2005        PMID: 15618952     DOI: 10.1038/sj.mp.4001571

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  57 in total

1.  Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes.

Authors:  Alexis C Edwards; Tim B Bigdeli; Anna R Docherty; Silviu Bacanu; Donghyung Lee; Teresa R de Candia; Arden Moscati; Dawn L Thiselton; Brion S Maher; Brandon K Wormley; Dermot Walsh; Francis A O'Neill; Kenneth S Kendler; Brien P Riley; Ayman H Fanous
Journal:  Schizophr Bull       Date:  2015-08-27       Impact factor: 9.306

2.  Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis.

Authors:  E Fuller Torrey; John J Bartko; Zhao-Rong Lun; Robert H Yolken
Journal:  Schizophr Bull       Date:  2006-11-03       Impact factor: 9.306

Review 3.  Genome-wide association studies: progress and potential for drug discovery and development.

Authors:  Stephen F Kingsmore; Ingrid E Lindquist; Joann Mudge; Damian D Gessler; William D Beavis
Journal:  Nat Rev Drug Discov       Date:  2008-03       Impact factor: 84.694

Review 4.  Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature.

Authors:  Ayman H Fanous; Kenneth S Kendler
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

5.  Modifiers and subtype-specific analyses in whole-genome association studies: a likelihood framework.

Authors:  Phil H Lee; Sarah E Bergen; Roy H Perlis; Patrick F Sullivan; Pamela Sklar; Jordan W Smoller; Shaun M Purcell
Journal:  Hum Hered       Date:  2011-08-17       Impact factor: 0.444

6.  Can genomics help usher schizophrenia into the age of RDoC and DSM-6?

Authors:  Ayman H Fanous
Journal:  Schizophr Bull       Date:  2015-05       Impact factor: 9.306

7.  Association between forkhead-box P2 gene polymorphism and clinical symptoms in chronic schizophrenia in a Chinese population.

Authors:  Wenwang Rao; Xiangdong Du; Yingyang Zhang; Qiong Yu; Li Hui; Yaqin Yu; Changgui Kou; Guangzhong Yin; Xiaomin Zhu; Lijuan Man; Jair C Soares; Xiang Yang Zhang
Journal:  J Neural Transm (Vienna)       Date:  2017-04-18       Impact factor: 3.575

8.  Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history.

Authors:  Sarah E Bergen; Colm T O'Dushlaine; Phil H Lee; Ayman H Fanous; Douglas M Ruderfer; Stephan Ripke; Patrick F Sullivan; Jordan W Smoller; Shaun M Purcell; Aiden Corvin
Journal:  Schizophr Res       Date:  2014-02-26       Impact factor: 4.939

9.  Evidence for a role of the NOS1AP (CAPON) gene in schizophrenia and its clinical dimensions: an association study in a South American population isolate.

Authors:  Barbara Kremeyer; Jenny García; Hanna Kymäläinen; Naomi Wratten; Gabriel Restrepo; Carlos Palacio; Ana Lucía Miranda; Carlos López; Margarita Restrepo; Gabriel Bedoya; Linda M Brzustowicz; Jorge Ospina-Duque; María Patricia Arbeláez; Andrés Ruiz-Linares
Journal:  Hum Hered       Date:  2008-12-15       Impact factor: 0.444

10.  Quantifying between-cohort and between-sex genetic heterogeneity in major depressive disorder.

Authors:  Maciej Trzaskowski; Divya Mehta; Wouter J Peyrot; David Hawkes; Daniel Davies; David M Howard; Kathryn E Kemper; Julia Sidorenko; Robert Maier; Stephan Ripke; Manuel Mattheisen; Bernhard T Baune; Hans J Grabe; Andrew C Heath; Lisa Jones; Ian Jones; Pamela A F Madden; Andrew M McIntosh; Gerome Breen; Cathryn M Lewis; Anders D Børglum; Patrick F Sullivan; Nicholas G Martin; Kenneth S Kendler; Douglas F Levinson; Naomi R Wray
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-01       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.